R&D In Brief
This article was originally published in Pharmaceutical Approvals Monthly
Pfizer halts figitumumab lung cancer trial: Pfizer has stopped a late-stage trial of its insulin-like growth factor 1 inhibitor figitumumab (CP-751,871) in metastatic non-small cell lung cancer, losing the lead in the new oncology space (1Pharmaceutical Approvals Monthly May 2008). Pfizer is continuing with an ongoing trial combining figitumumab with Roche/Genentech's Tarceva in NSCLC; a third planned Phase III trial has not yet started. The Phase III lung cancer trial was halted after the independent data safety monitoring board detected an imbalance in serious adverse events, including fatalities, in the '871, carboplatin and Taxol arm. Pfizer, which has made a major push into oncology, has faced other recent setbacks in cancer, with failed trials of Sutent (sunitinib) in breast cancer and the investigational axitinib in pancreatic cancer (2"The Pink Sheet" DAILY, April 2, 2009)
You may also be interested in...
Further delay for Prevnar 13: FDA has not yet completed its review of Pfizer's Prevnar 13 vaccine for pneumococcal disease and therefore the review will continue beyond the Dec. 30 user fee deadline. It's not clear how much longer the review will take and there was no explanation for the delay, but there was no indication that additional information was sought, according to the drug maker's Dec. 30 statement. The vaccine is under priority review and FDA already used its one-time extension of the user fee period to move the original action date of Sept. 30 to the December date, after additional manufacturing data was submitted. An FDA advisory committee voted 10 to 1 on Nov. 18 to recommend the product, although the panel did not endorse a broad claim for otitis media (1"The Pink Sheet," Nov. 23, 2009). European marketing authorization was granted on Dec. 11
Failed single-agent trial is small setback for Sutent, analyst says. Pfizer has three combination trials also ongoing in breast cancer settings.
Pfizer's CP-751,871 for metastatic non-small cell lung cancer recently became the first insulin-like growth factor 1 receptor inhibitor to enter Phase III trials, as the class gains popularity and strength